Dexamethason 4 mg GALEN®

DRUG3 trials

Sponsors

ADC Therapeutics S.A., Celgene Corp.

Conditions

Diffuse Large B-Cell Lymphoma (DLBCL)Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 1

An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants with Relapsed or Refractory Multiple Myeloma

RecruitingCTIS2023-509384-25-00

Celgene Corp.Relapsed or Refractory Multiple Myeloma (RRMM)

Start: 2022-12-30Target: 56Updated: 2025-10-10

Phase 3

A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)

Active, not recruitingCTIS2023-503916-33-00

ADC Therapeutics S.A.Diffuse Large B-Cell Lymphoma (DLBCL)

Start: 2021-03-24Target: 277Updated: 2025-07-17

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib And Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib And Dexamethasone (PVd) In Subjects With Relapsed Or Refractory Multiple Myeloma (RRMM): Successor-1

RecruitingCTIS2023-509859-13-00

Celgene Corp.Relapsed or Refractory Multiple Myeloma (RRMM)

Start: 2022-11-09Target: 322Updated: 2025-09-25